Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: a multicenter phase II trial
Y Wang, M Zhang, W Song, Q Cai… - American Journal of …, 2022 - Wiley Online Library
Angioimmunoblastic T‐cell lymphoma (AITL) is a common type of peripheral T‐cell
lymphoma (PTCL) with a poor prognosis, and an effective first‐line therapy is lacking …
lymphoma (PTCL) with a poor prognosis, and an effective first‐line therapy is lacking …
Management of angioimmunoblastic T-cell lymphoma (Aitl) and other T follicular helper cell lymphomas (Tfh ptcl)
H Ma, OA O'Connor, E Marchi - Seminars in Hematology, 2021 - Elsevier
Despite the remarkable improvements in the treatment and outcome of patients with
aggressive B-cell lymphoma, the peripheral T-cell lymphomas (PTCL) continue to carry a …
aggressive B-cell lymphoma, the peripheral T-cell lymphomas (PTCL) continue to carry a …
[HTML][HTML] Biological insights into the role of TET2 in T cell lymphomas
SA Carty - Frontiers in Oncology, 2023 - ncbi.nlm.nih.gov
Peripheral T cell lymphomas (PTCL) are a heterogenous group of mature T cell lymphomas
with an overall poor prognosis. Understanding the molecular heterogeneity in PTCL …
with an overall poor prognosis. Understanding the molecular heterogeneity in PTCL …
[HTML][HTML] Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T‐cell …
V Camus, P Etancelin, F Drieux… - Clinical Case …, 2023 - ncbi.nlm.nih.gov
Peripheral T‐cell lymphomas have an aggressive disease course associated with poor
outcomes. We report a young patient with highly pretreated relapsed/refractory nodal …
outcomes. We report a young patient with highly pretreated relapsed/refractory nodal …
Approved Agents in the Relapsed or Refractory Setting, Excluding Brentuximab Vedotin
H Ma, OA O'Connor - The Peripheral T‐Cell Lymphomas, 2021 - Wiley Online Library
It has been a decade since the approval of pralatrexate, a novel antifolate drug with lineage
selective activity in patients with relapsed or refractory peripheral T‐cell lymphomas (PTCL) …
selective activity in patients with relapsed or refractory peripheral T‐cell lymphomas (PTCL) …